- 88% average reduction in PTSD symptoms one month after treatment
- 87% reduction in depression; 81% reduction in anxiety
- Disability scores dropped from 30.2 (mild-moderate disability) to 5.1 (no disability)
- No unexpected or serious adverse events
- Significant improvements in concentration, memory, and executive function
The Study
In January 2024, Stanford University researchers published what may be the most important psychedelic medicine study ever conducted. The paper, "Magnesium–Ibogaine Therapy in Veterans with Traumatic Brain Injuries," appeared in the prestigious journal Nature Medicine and sent shockwaves through the psychiatric and neuroscience communities worldwide.
The study followed 30 special operations veterans — elite soldiers from units including Delta Force and Navy SEALs — all of whom had experienced repeated blast exposures and head trauma during combat. These were not ordinary PTSD cases. These were men who had lived through multiple deployments, sustained traumatic brain injuries, and were struggling with the most severe and treatment-resistant forms of psychological disability.
The Participants
Of the 30 participants, 23 met clinical criteria for PTSD, 14 for anxiety disorder, and 15 for alcohol use disorder. In their lifetimes, 19 had experienced suicidal ideation and seven had attempted suicide. Before treatment, their average disability rating on the World Health Organization Disability Assessment Schedule was 30.2 — corresponding to mild to moderate disability that significantly impaired their ability to work, maintain relationships, and live independently.
All participants had independently scheduled themselves for treatment at Ambio Life Sciences clinic in Mexico, where ibogaine is legal and administered under full medical supervision with cardiac monitoring and magnesium co-administration to mitigate cardiovascular risk.
The Results
One month after a single ibogaine treatment session, the results were extraordinary:
Perhaps most remarkably, post-treatment disability scores dropped to an average of 5.1 — a level indicating essentially no disability. In one month. With a single treatment session.
The Neural Mechanisms
In a follow-up neuroimaging study published in Nature Mental Health in July 2025, Dr. Nolan Williams and his team analyzed EEG and MRI data from the same cohort. They discovered that veterans who improved most in executive function showed increased theta brain wave activity — associated with neuroplasticity and cognitive flexibility. Those with the greatest PTSD symptom reductions showed decreased cortical complexity, suggesting a resetting of the hyperactivated stress-response system.
"I think this may emerge as a broader neuro-rehab drug. I think it targets a unique set of brain mechanisms and can help us better understand how to treat other forms of PTSD, anxiety and depression that aren't necessarily linked to TBI." — Dr. Nolan Williams, Stanford University
What This Means for Israel
Israel faces a mental health catastrophe of historic proportions. Since October 7, 2023, over 85,000 IDF soldiers have received psychological treatment. The Defense Ministry's own projections show a 180% increase in PTSD cases by 2028, with one caseworker for every 850 veterans.
The Stanford study, combined with Israel's existing world-class medical infrastructure and its history of innovative drug policy (see: the national medical cannabis program pioneered by Boaz Wachtel), positions Israel perfectly to lead on ibogaine. What is needed now is political will, regulatory courage, and the foundation of institutions like ours to advocate, educate, and push for clinical access.
References
- Cherian, K.N. et al. (2024). Magnesium–ibogaine therapy in veterans with traumatic brain injuries. Nature Medicine. nature.com
- Stanford Medicine News (2024). Psychoactive drug ibogaine effectively treats traumatic brain injury in special ops military vets. med.stanford.edu